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Budesonide, a potent glucocorticoid, is used for the treatment of inﬂammatory bowel diseases. Current available oral formulations
of budesonide have low eﬃcacy against ulcerative colitis because of the premature drug release in the upper part of the
gastrointestinal tract. In this paper a pH- and time-controlled colon-targeted pellet-based tablet of budesonide was established.
Pellet cores were prepared by extrusion-spheronization method and further coated with xanthan gum (barrier layer), Eudragit
NE30D and L30D55 combination (inner layer), and Eudragit FS30 (as enteric layer) sequentially to achieve the required release
proﬁle. The coated pellets then compressed into tablets using inert tabletting granules of Cellactose or Pearlitol. Release studies,
performed in simulated gastric, intestinal, and colon pH were used in sequence to mimic the gastrointestinal transit. The inﬂuence
of formulation variables like barrier layer thickness, inner layer composition, and enteric coat thickness on drug release were
investigated and the coated pellets that contained 12% weight gain in xanthan gum layer, Eudragit L30D55 and Eudragit NE30D
with a ratio of 3:7 in inner layer with 30% weight gain and 25% weight gain in Eudragit FS layer were found to protect the
drug release in stomach and small intestine and 83.35 ± 2.4 of budesonide was released at 24h. The drug release from the tablets
prepared using 40% Cellactose 80 as tableting excipient was found to be closely similar to that of uncompressed pellets.
1.Introduction
Controlled-release multiunit dosage forms (e.g., pellets,
granules, or microparticles) are becoming more and more
important on the pharmaceutical market, as they provide
several advantages compared to single-unit dosage forms
(e.g., tablets or capsules) [1]. With regard to the ﬁnal dosage
form, the multiunits can be ﬁlled into hard gelatin capsules
[2] or be compressed into disintegrating tablets [3, 4]. The
advantages of tableting multiunits include less diﬃculty in
oesophageal transport, and thus a better patient compliance.
Tablets can be prepared at a lower cost because of the
higher production rate of tabletting process. The expensive
control of capsules integrity after ﬁlling is also eliminated.
In addition, tablets containing multiunits could be scored
withoutlosingthecontrolledreleaseproperties,whichallows
a more ﬂexible dosing regimen [5].
One challenge in the production of such systems is
maintaining the desired drug release after compaction as the
application of compaction pressure can lead to structural
changes in the ﬁlm coating and consequently altered drug
release [6]. The compression-induced changes in the struc-
ture of a ﬁlm coating may depend on formulation factors
such as mechanical properties of the ﬁlm and incorporated
excipients of pellets [7]. Another important parameter that
should be considered is choosing of proper cushioning2 Journal of Drug Delivery
agent to prevent of undesirable fusion of coated pellets
by the compression [8]. In this study, a colon delivery
formulation of budesonide was designed based on pH and
time-dependent approach where ﬁlm-coated pellets were
compressed into multiparticulate tablets. Budesonide, a
potent glucocorticoid, is a standard drug for the localized
treatment of inﬂammatory bowel diseases [9]. Current
available oral formulations of budesonide have low eﬃcacy
against ulcerative colitis (UC) because of the premature drug
release in the upper part of the gastrointestinal tract (GIT)
[10]. In this study, triple-layer-coated pellets of budesonide
were developed for colonic targeting. The pellets were
prepared by extrusion/spheronization method and further
coated sequentially with various polymers. Then they were
compressed into tablets using Cellactose 80 or Pearlitol 200
granules as tabletting excipient. The expected in vitro release
pattern selected for the colon targeting was no drug release
in simulated gastric ﬂuid and not more than 10% of drug
release up to the end of small intestine (4hrs) and more than
80% of drug release up to 24hrs in the simulated colon.
2.MaterialsandMethods
2.1. Materials. Budesonide was obtained as a gift sample
from Astra Zeneca (UK). Eudragit FS 30 D, Eudragit NE30D,
and Eudragit L30D55 were donated by Evonik Degussa
Corporation(Germany).FMC(Ireland)providedthemicro-
crystalline cellulose as Avicel PH 101 and Avicel RC581.
Talc and triethyl citrate (TEC) were obtained from Kirsh
Pharma(Germany);lactosemonohydrate200andCellactose
80(Coprocessedlactose-cellulose-compound)wereobtained
from Meggle (Germany). Pearlitol 200 (direct compressible
mannitol) was obtained from ROQUETTE (France). Xan-
than gum was obtained from Arthur Branwell (UK). All
other materials used were of analytical reagent grade and
purchased from Merck Co. (Darmstadt, Germany).
2.2. Preparation of Pellets by Extrusion/Spheronization. Core
pellets containing budesonide (1.5% w/w), Avicel PH 101
(6%w/w),AvicelRC581(24%w/w)andlactose(68.5%w/w)
were prepared by extrusion-spheronization using model 20
extruder and model 250 spheronizer (Caleva, UK). Distilled
water was used as granulation liquid. They were dried at
roomtemperaturefor24h.Pelletswiththesizerangeof840–
1000µm were used for subsequent coating.
2.3. Preparation of Budesonide-Coated Pellets. Budesonide
containing pellet cores were coated with various polymers
(Figure 1) using a top spray ﬂuidized bed coater (VECTOR
Corporation, Marion, Iowa) at coating conditions as shown
in Table 1.
2.3.1. Inner Coat. A dispersion containing 0.25% w/v of
xanthan gum prepared by dispersing gum in 70: 30 ethanol:
water mixture containing plastisizer, triethyl citrate (TEC)
(5% w/v, based on amount of solvent).
Before addition of plasticizer, gum mucilage was stirred
gently for a period of 10min with magnetic stirrer and the
dispersion was allowed to equilibrate for a period of 3h. The
solution was allowed to stand at room temperature for 24h.
2.3.2. Middle Coat. Eudragit NE30D and Eudragit L30D55:
the mixture of these two polymers (9:1, 8:2, and 7:3 ratio
(w/w)) was added to a beaker, placed on a magnetic stir
plate and mixed with a slow agitation for a period of 1h.
Talc, equal to 50% (w/w) of the total dry polymer weight
and TEC equal to 20% (w/w) of Eudragit L30D55 dry
polymer weight were added in a separate volume of water
and dispersed via high shear mixing. The dispersion was
then added to the former blend of Eudragit dispersion. The
resulting dispersion had a total solid content of 15% and was
allowed to mix for a further 10min prior to application to
the budesonide pellets.
2.3.3. Outer Coat. Eudragit FS30D aqueous dispersion was
diluted twice with water before use. Talc (50% on dry
polymer weight) and TEC (10% on dry polymer weight)
were added as glidant and plasticizer, respectively. After each
coating run, pellets were ﬂuidized for a further 15min before
checking the weight gain and then subsequently cured. A
series of coated products were produced with diﬀerent ﬁlm
thicknessesandquantiﬁedbythetotalweightgain(%TWG).
The compositions of various pellet formulations are
shown in Table 2.
2.4. Tabletting of Coated Pellets. To produce multiple unit
tablets, the optimized batch of coated pellets in size range of
1190–1410µm were mixed with diﬀerent ratios and diﬀerent
proportion of the inert tabletting granules. Diluents of
Cellactose or Pearlitol granules were used for formulation
development. The granules were prepared using wet granu-
lation method. Distilled water (the granulating liquid) was
added to Cellactose or Pearlitol and mixed for 10min to
produce a wet mass of suitable consistency, which was passed
through 1mm diameter sieve and were dried in an oven
at 50◦C. The coated budesonide pellets and inert granules
were compressed into tablets using a single punch-tabletting
machine ﬁtted with round ﬂat faced 11.6- mm- diameter
punches and dies at 70N compressions to get suﬃcient
strength. The compositions of various tablet formulations
are shown in Table 2. Magnesium stearate was used as a
lubricant in all formulations (1%).
2.5. In Vitro Release Studies for Budesonide Pellets and Tablets.
The dissolution performance of the coated pellets and
prepared tablets was tested using USP method 2 (rotating
paddle at 50rpm, 37 ± 0.5◦C, n = 6). For the ﬁrst two
hours of the test, 0.1N HCl (pH 1.2) (250mL) was used
as the test medium. After two hours, the test medium was
changedtophosphatebuﬀersolution(PBS)pH7.4(250mL)
for four hours and ﬁnally to PBS pH 6.8 (250mL) for 18h.
In all drug release studies, 0.5 percent (w/v) of sodium lauryl
sulphate was used in each dissolution medium to maintain
sink conditions [11]. Samples were withdrawn from the
dissolution vessels at regular intervals and the concentration
of budesonide in solution was monitored by HPLC method
described below [12]. All tests were done on 6 tablets of eachJournal of Drug Delivery 3
FS30D ﬁlm-coating layer
Eudragit NE/L30D55 ﬁlm-coating layer
Xanthan gum ﬁlm-coating layer
Pellet core
Figure 1: Schematic of the multilayer ﬁlm coated pellet of Budesonide.
Table 1: Operating conditions for the coating experiments.
Operating condition Xanthan gum Eudragit NE30D/L30D-55 Eudragit FS 30D
Before coating preheating to (◦C) — — —
Coating nozzle diameter (mm) 0.8 1.2 1.2
Spraying rate (g/min) 4 2 2
Inlet air temperature (◦C) 60 30–32 35–42
Outlet air temperature (◦C) 56-57 25–28 25–28
Curing on trays 24hrs at 40◦C2 4 h r s a t 4 0 ◦C2 4 h r s a t 4 0 ◦C
formulationandthemeanofresultswasconsideredinrelease
proﬁles.
2.6. Budesonide Analysis. The quantitative determination of
budesonide in assay and dissolution studies was performed
by HPLC method equipped with UV detector using dexam-
ethasoneasaninternalstandard.Theanalysiswascarriedout
by using a Shimpack C8 column (150mm × 4.6mm, 5mm
particle size) at a wavelength of 244nm. The mobile phase
consisted of acetonitrile, monobasic potassium phosphate
(0.025M) (55:45, pH of 3.2). The ﬂow rate was 1.0mL/min
and injection volume, 20µL. Quantitation was achieved by
measurement of the peak area ratios of the drug to the
internal standard. The retention time of the budesonide
chromatographic peak was found at 5min.
2.7. Stability Studies. Optimized formulation was kept in
the humidity chamber maintained at 40◦C and 75% relative
humidity for 3 months. At the end of study, the formulation
was evaluated for drug content and in vitro release proﬁle.
2.8. Statistical Analysis. The data of drug release were
analyzed using one-way analysis of variance (ANOVA). The
release proﬁles of optimized formulation were compared in
stability and reproducibility tests using model-independent
approach, with the similarity factor (f2)d e ﬁ n e db y[ 13].
f2 = 50+log
⎧
⎪ ⎨
⎪ ⎩
⎡
⎣1+
 
1
n
  n  
t=1
n(Rt −Tt)
2
⎤
⎦
−0.5
×100
⎫
⎪ ⎬
⎪ ⎭
. (1)
The two release proﬁles were considered to be similar if f2
value was more than 50 (between 50 and 100).
3. Results and Discussion
During this study, budesonide pellet core formulation was
developed using extrusion-spheronization technique. These
pellets were spherical in shape and showed suitable hardness
to withstand coating conditions. The pellets had a 91 ±
2.83% budesonide release after 2hrs in pH 6.8, so any later
slow release could be attributed to the coating system(s)
being studied.
3.1. In Vitro Drug Release from Coated Pellets . In designing
anidealcolon-targeteddrugdeliverysystem,thedrugshould
not be released in the stomach and small intestine, and the
release of drug must be completed within the residence time
of the dosage form in the colon. In the case of the present
study, it was assumed that for colon-targeting purpose, an
18 h extended release formulation with a delay in onset of
about 6h would be suitable. This lag time would ensure the
passage of the formulation intact through the stomach and
small intestine without noticeable drug loss.
The approach of using mixed polymeric coating of
Eudragit NE 30D and Eudragit L30D-55 blends in time
release applications has been reported previously [14].
Eudragit NE30D is an acrylic copolymer with neutral
groups that enables controlled time release of the active
ingredient by pH-independent swelling [5]. As its softening
temperatureisca.12◦C,itformsveryﬂexibleﬁlmsuitablefor
compression with an elongation limit up to 300% due to the
lack of strong interchain interaction [5]. Eudragit L30D-55
is an anionic polymer, which contains COOH as a functional
group that dissolves at pH > 5.5. L30D-55 is known to be
quite rigid with 20% elongation using 10% triethyl citrate as
a plasticizer [15].
Four representative formulations of coated pellets were
prepared by varying the ratio of Eudragit L to Eudragit NE
as shown in Table 2. The results of in vitro drug release4 Journal of Drug Delivery
Table 2: Formulation details of pellets and multiunit tablets.
Formulation
code Dosage form Pellet composition Inert tabletting excipient
( w / w %o ft a b l e tw e i g h t )
Barrier coat Xanthan gum
(%TWG)∗
Inner coat L30D/NE30D
(ratio) (%TWG)
Outer coat FS 30D
(%TWG)
F1 Coated pellets — (0:10) (10) — —
F2 Coated pellets — (0:10) (20) — —
F3 Coated pellets — (0:10) (30) — —
F4 Coated pellets — (1:9) (30) — —
F5 Coated pellets — (2:8) (30) — —
F6 Coated pellets — (3:7) (30) — —
F7 Coated pellets 2.5 (3:7) (30) — —
F8 Coated pellets 5 (3:7) (30) — —
F9 Coated pellets 10 (3:7) (30) — —
F10 Coated pellets 10 (3:7) (30) 12 —
F11 Coated pellets 10 (3:7) (30) 25 —
F12 Multiple unit tablet 10 (3:7) (30) 25 30 (Pearlitol)
F13 Multiple unit tablet 10 (3:7) (30) 25 50 (Pearlitol)
F14 Multiple unit tablet 10 (3:7) (30) 25 30 (Cellactose)
F15 Multiple unit tablet 10 (3:7) (30) 25 40 (Cellactose)
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Figure 2: Eﬀect of coating level of Eudragit NE 30D on budesonide
release.
studies (Figure 2) indicated that increasing the polymer
coating level of Eudragit NE30D from 15% to 30% (w/w)
caused a signiﬁcant reduction in the drug release. The pellets
coated with Eudragit NE30D at a coating level of 30% (w/w)
showed negligible release during the 6h of dissolution test
in HCl 0.1N and PBS (pH 7.4). Nevertheless, at the end of
dissolution studies, the mean percent drug released was only
58%.
The eﬀect of coating with Eudragit NE30D: Eudragit
L30D-55 blend on in vitro drug release for three diﬀerent
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Figure 3: Eﬀect of the ratio of Eudragit L 30D 55 to Eudragit NE
30D on budesonide release.
batches of weight gains of 30% (w/w) is shown in Figure 3.
Batches F4,F 5,a n dF 6 released no drug in acidic medium,
12.8%, 18.5%, and 23.3%, at the end of 6hrs, while 57.4%,
70.5%, and 84.3% of drug was released at the end of
24hrs, respectively. In PBS (pH 7.4), the enteric polymer
(Eudragit L30D-55) dissolved or leached out, thus increasing
the permeability of the coating, oﬀering less resistance for
budesonide diﬀusion. Although drug release of formulation
F6 insimulatingintestinalﬂuidwasnotoptimal,the3:7ratio
of Eudragit L30D-55 to Eudragit NE30D was selected forJournal of Drug Delivery 5
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Figure 4: Budesonide release proﬁles from pellets with an inner
coat of xanthan gum and an outer coat of Eudragit L 30D 55:
Eudragit NE 30D (3:7 ratio) showing the eﬀect of coating level of
xanthan gum on budesonide release proﬁle.
further studies in consideration of the near complete release
at the end of dissolution run.
To achieve a desired release proﬁle, a modiﬁcation in
the coating pattern was made. Xanthan gum as a release
retardant polymer was chosen as the coating polymer for
inner coating layer. Xanthan gum rapidly forms a gel layer
that retards seeping of dissolution ﬂuids into the core
pellets and reduces the diﬀusion of drug from the core
to negligible level and decreases the drug release from the
formulation. Figure 4 shows the release of budesonide from
pellets coated with various coating levels of xanthan gum
as inner coating. Coating with 2.5% (w/w) xanthan gum
(F7)w a sn o ts u ﬃcient, and the drug release was the same as
F6(P>0.05). However, increasing the xanthan gum coating
level to 12% (w/w) resulted in lower release in simulated
intestinal ﬂuid signiﬁcantly (P<0.05) with no eﬀect on the
total amount of drug released in 24hrs.
It seems that rapid swelling and rapid erosion properties
of xanthan gum played an important role in this regard.
By observing the above results, it was found that F9 batch
released12.16 ±0.83%ofthedruginthesimulatedintestinal
ﬂuidandreleasedupto84.54±0.17%attheendofthe24hrs
in the simulated colonic medium considered as suitable
batch for colon targeting. To further provids mechanical
resistanceandresistanceagainsttheinﬂuenceofgastricjuice,
diﬀerentcoatingthicknessesofEudragitFS30Dwereapplied
to budesonide pellets from 12 to 25% weight gain. Eudragit
FS 30D is an anionic polymer of methacrylic acid and
methacrylates that contains −COOH as a functional group
and dissolves at pH 7. At the same time, FS 30D can achieve
up to 300% elongation that enables decreased damage to the
pellet coating during tabletting [16]. All Eudragit FS 30D
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Figure 5: Release proﬁle of selected coated pellets and multiunit
tablets prepared with Cellactose in simulated GI ﬂuid pH.
coated pellets with 12%, as well as 20% (w/w) weight gain
furthersuppressedbudesonidereleaseinsimulatedintestinal
ﬂuid but had no signiﬁcant eﬀect on total budesonide
released at the end of dissolution run (Figure 5). As a
thicker coating can prevent damage due to compression
compared to the thinner coating and as the ability of pellets
to undergo plastic and elastic deformation increases with
increasing coating level [8], formulation F11 was selected
to be combined with the inert tabletting granules in the
preparation of multiple unit tablets.
3.2. In Vitro Drug Release from Tablets. A major problem
in compaction of coated pellets is that the coating can
rupture on compaction, resulting in signiﬁcant diﬀerences
in dissolution proﬁles of coated pellets prior to and after
compaction. There are two approaches in pellet tabletting:
tablettingofpelletswithoutotherexcipientsandtablettingof
pellets together with pharmaceutically acceptable excipients.
The approach of pellets compacting without other excipients
does not have the problem of particle segregation, but
formulation of pellet cores and also the coating of produced
tablets is very diﬃc u l t .P e l l e tc o r e sm u s tb ed e f o r m a b l e
enough so that they form coherent tablets, and the coatings
of pellets must be able to withstand compacting without
damages, which can be ensured by formulating the coating
of multiple units in such a way that the coating possesses
improved elasticity. The approach of compacting of pellets
together with tabletting excipients moderates requirements
for the pellet coating elasticity, since plastically deformable
tabletting excipients are able to partly absorb compaction
forces and protect pellets from mechanical damages. This
approach also enables easier obtaining of pellet-based tablets
that have appropriate hardness and friability. To develop6 Journal of Drug Delivery
Table 3: Physical Characteristics of multiunit tablets of budesonide.
Formulation Code Uniformity of weight [mg] Hardness [N] Friability [%] Content uniformity
RSD% RSD%
F12 448 ± 12 68 0.72 2.917 ± 11.85
F13 622.9 ± 7.23 73 0.65 3.113 ± 7.29
F14 436.9 ± 4.28 64 0.14 3.046 ± 3.9
F15 513 ± 2.69 67 0.16 3.059 ± 1.85
multiunit tablets of budesonide, coated pellets of F11 batch
were mixed with Cellactose or Pearlitol granules as cush-
ioning agents and compressed. The amount of cushioning
agent was modiﬁed and studied for their eﬀect on physical
parameters of tablets and dissolution. Four tablet formula-
tions were studied (F12,F 13,F 14 and F15)( Table 2)w h i c h
were prepared at the same adjustment of press machine.
Physical parameters of the tablets are shown in Table 3.A l l
formulations were highly compressible resulting in tablets
of enough crushing strength (Table 3). Friability of the
tablets was also in the limits below 1% after 4min of
testing. But friability results were signiﬁcantly lower with
tablets F14 and F15. The results presented in Table 3 show
that the content uniformity and average weight of F12
and F13 batches signiﬁcantly changed during the tabletting.
In contrast, the use of Cellactose produced tablets with
improved content uniformity and average weight (F14 and
F15). For these reasons F12 and F13 were excluded from
further investigations. The in vitro drug release patterns of
the F14 and F15 batches were compared and also compared
to the pellets before compression as shown in Figure 5.I n
the case of batch F14, 7.96% of the drug was released after
2hrs in gastric pH compared to negligible release from the
pellets before compression. Then, the release became 14.32%
after 4hrs in phosphate buﬀer (pH 7.4), compared to 8.16%
released from the pellets before compression. On the other
hand, there was no diﬀerence in budesonide release from F15
and uncompressed pellets and the f2 value was 74.85. We
conclude that the increasing concentration of Cellactose to
40%minimizescontactofmultipleunitswitheachotherand
protects the pellets from deformation under compression
pressure.
Recently a new technique has been introduced as MMX
technology for production of colon-targeted tablets. Mul-
timatrix (MMX) technology is a promising new delivery
system that can improve eﬃcacy of current and new drugs,
augmenting targeting to the aﬀectedtract,therebyincreasing
response and remission rates for those drugs in patients with
IBD. This technology comprises hydrophilic and lipophilic
excipients, enclosed within a gastroresistant, pH-dependent
coating of acrylic copolymers, which delay the release until
the tablet reaches the indicated intestinal location where the
programmed dissolution begins. The results of various stud-
ies involving MMX drugs have been published. Mesalamine
MMX induces clinical and endoscopic remission in patients
with mild-to-moderate ulcerative colitis (UC) compared
with placebo. In a pilot study involving ten patients with UC,
eﬃcacy of heparin-MMX as an IBD therapy was observed.
Positive results have also been observed with MMX budes-
onide 9mg extended-release tablets in phase I studies [17].
Budesonide-MMX induced a fast and signiﬁcant clinical
improvement of active left-sided UC without suppression of
adrenocortical functions and without important toxicity [? ].
In comparison with Budesonide-MMX tablets, the designed
pellet based tablets of our study contains 3mg budesonide
and is a pH- and time-controlled colon-targeted delivery
system. In addition, tablets containing multiunits could
be scored without losing the controlled release properties,
which allows a more ﬂexible dosing regimen and a more
uniform spreading of the pellets through the colon.
3.3. Accelerated Stability Study . Figure 5 shows the release
proﬁles of optimized formulation (F15) at zero time and
during storage period. No signiﬁcant diﬀerence was found
between the drug release proﬁles of the stored samples after
three-monthstorageunderacceleratedconditionsand f2 was
66.4. There were no signs of visually distinguishable changes
in appearance and color of pellets. The drug content was
comparable with that of the control samples and within
limits (±10%). On the basis of these results, it can be
concluded that the formulation had enough stability under
accelerated stability test conditions for three months.
4. Conclusions
The study discusses the formulation of colon targeted multi
unit tablets of budesonide for the treatment of UC. The
pellets prepared for colon targeting of drug suﬃciently
protected drug release in the simulated environment of
stomach as well as small intestine, and majority of drug
release occurred in the simulated environment of colon. The
budesonide-loaded pellets coated with 12% (w/w) xanthan
gum, 30% (w/w) mixture of Eudragit NE: Eudragit L30D-
55 (7: 3 ratio) and 25% (w/w) Eudragit FS 30D exhibited a
promising dissolution proﬁle. Cellactose granules as tablet-
ting excipient, not only produced tablets with acceptable
physical parameters, but also were able to protect the coated
pelletsfromdamageduringtablettingandpreventpremature
drug release. The developed formulations were considered
stable during 3 months of storage at accelerated stability
conditions. Although the proposed formulation is moder-
ately complex, its manufacture is simple and reproducible,
and could also be easily manufactured on a large-scale in a
reasonable processing time using standard pharmaceutical
equipments. However, it should not be forgotten that the
in vitro studies of the eﬀects of pH and time on the releaseJournal of Drug Delivery 7
characteristics are really only a prelude to in vivo studies in
human volunteers and then in patients with active ulcerative
colitis. It should be considered that colonic pH changes in
the presence of active inﬂammation, that small bowel transit
usually slows with severe colitis, and that there is often stasis
in the right colon in the presence of active distal disease.
Thus, in vivo data are needed to really know whether the
recommended formulation is going to be relevant.
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